Immunosurveillance in clinical cancer management

Immune checkpoint therapy—current perspectives and future directions

(2023) Padmanee Sharma et al.   CELL

Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma

(2023) Alexander C.J. van Akkooi et al.   EUROPEAN JOURNAL OF CANCER

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

(2023) Sapna P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

(2023) Heather Wakelee et al.   NEW ENGLAND JOURNAL OF MEDICINE

A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers

(2023) Marine Fidelle et al.   SCIENCE

Trial watch: chemotherapy-induced immunogenic cell death in oncology

(2023) Jenny Sprooten et al.   OncoImmunology

Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer

(2023) Vincent Carbonnier et al.   OncoImmunology

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer

(2023) François Ghiringhelli et al.   EBioMedicine

Anti-TIGIT therapies for solid tumors: a systematic review

(2023) A. Rousseau et al.   ESMO Open

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics

(2023) Valentina Tateo et al.   Pharmaceuticals

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer

(2023) Mariano Provencio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

(2022) Reinhard Dummer et al.   JOURNAL OF CLINICAL ONCOLOGY

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

(2022) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer

(2022) Maxime Meylan et al.   IMMUNITY

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

(2022) Michael Lim et al.   NEURO-ONCOLOGY

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial

(2022) Antonio Omuro et al.   NEURO-ONCOLOGY

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

(2022) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Potential of the Gut Microbiome to Reshape the Cancer Therapy Paradigm

(2022) Longsha Liu et al.   JAMA Oncology

Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era

(2022) Laura Kalfeist et al.   Cells

Cancer vaccines

(2022) John T. Schiller et al.   CANCER CELL

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

(2022) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

(2022) Andrea Cercek et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis

(2022) Xiaoyu Guo et al.   Frontiers in Immunology

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer

(2022) Hualin Chen et al.   Frontiers in Immunology

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer

(2022) Peng Liu et al.   OncoImmunology

Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment

(2022) Emily Pei-Ying Lin et al.   JAMA Network Open

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

(2022) Melissa L. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

(2022) Neil D. Gross et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quality assurance of hematopoietic stem cells by macrophages determines stem cell clonality

(2022) Samuel J. Wattrus et al.   SCIENCE

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis

(2022) Jincheng Wang et al.   Frontiers in Oncology

Germline genetic contribution to the immune landscape of cancer

(2021) Rosalyn W. Sayaman et al.   IMMUNITY

Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance

(2021) Heng Lin et al.   CANCER CELL

Prognostic value of the postoperative neutrophil-lymphocyte ratio in solid tumors: A meta-analysis

(2021) Meilong Wu et al.   PLoS One

Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors

(2021) Franziska Hauth et al.   JAMA Oncology

Plasma proteomics identifies Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance

(2021) Y. Loriot et al.   ANNALS OF ONCOLOGY

Autophagy in major human diseases

(2021) Daniel J Klionsky et al.   EMBO JOURNAL

ATP and cancer immunosurveillance

(2021) Oliver Kepp et al.   EMBO JOURNAL

Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!

(2021) Michele Maio et al.   EUROPEAN JOURNAL OF CANCER

Atlas of clinically distinct cell states and ecosystems across human solid tumors

(2021) Bogdan A. Luca et al.   CELL

A review of cancer immunotherapy toxicity

(2020) Lucy Boyce Kennedy et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

(2020) Kohei Shitara et al.   JAMA Oncology

Immunomodulation by targeted anticancer agents

(2020) Giulia Petroni et al.   CANCER CELL

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

(2020) Thierry André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

(2019) Zhijie Wang et al.   JAMA Oncology

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

(2019) Steve Lu et al.   JAMA Oncology

Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity

(2019) Wei Xie et al.   OncoImmunology

Immunosuppression by Mutated Calreticulin Released from Malignant Cells

(2019) Peng Liu et al.   MOLECULAR CELL

Cytosolic DNA Sensing in Organismal Tumor Control

(2018) Claire Vanpouille-Box et al.   CANCER CELL

A Believer’s Overview of Cancer Immunosurveillance and Immunotherapy

(2018) Olivera J. Finn   JOURNAL OF IMMUNOLOGY

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

(2016) Joseph L. Benci et al.   CELL

The Basis of Oncoimmunology

(2016) A. Karolina Palucka et al.   CELL

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

(2016) Christina Pfirschke et al.   IMMUNITY

Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy

(2016) Ruth Exner et al.   Cancer Medicine

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Autophagy in malignant transformation and cancer progression

(2015) L. Galluzzi et al.   EMBO JOURNAL

Natural and therapy-induced immunosurveillance in breast cancer

(2015) Guido Kroemer et al.   NATURE MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

(2015) E. Vacchelli et al.   SCIENCE

Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer

(2015) Jitka Fucikova et al.   Frontiers in Immunology

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

(2014) Antonella Sistigu et al.   NATURE MEDICINE

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

(2013) Jedd D. Wolchok et al.   Annals of the New York Academy of Sciences

Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists

(2013) T Yamazaki et al.   CELL DEATH AND DIFFERENTIATION

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape

(2012) Bradley N Bidwell et al.   NATURE MEDICINE

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

(2012) Y. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

(2011) M. Michaud et al.   SCIENCE

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

(2009) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY